Literature DB >> 22684221

p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma.

Riley E Alexander1, Yingchuan Hu, Jennifer B Kum, Rodolfo Montironi, Antonio Lopez-Beltran, Gregory T Maclennan, Muhammad T Idrees, Robert E Emerson, Thomas M Ulbright, David G Grignon, John N Eble, Liang Cheng.   

Abstract

Squamous cell carcinoma of the urinary bladder is unusual and of unknown etiology. There is a well-established association between human papillomavirus (HPV) infection and the development of cervical and head/neck squamous cell carcinomas. However, the role of HPV in the pathogenesis of squamous cell carcinoma of the urinary bladder is uncertain. The purposes of this study were to investigate the possible role of HPV in the development of squamous cell carcinoma of the urinary bladder and to determine if p16 expression could serve as a surrogate marker for HPV in this malignancy. In all, 42 cases of squamous cell carcinoma of the urinary bladder and 27 cases of urothelial carcinoma with squamous differentiation were investigated. HPV infection was analyzed by both in situ hybridization at the DNA level and immunohistochemistry at the protein level. p16 protein expression was analyzed by immunohistochemistry. HPV DNA and protein were not detected in 42 cases of squamous cell carcinoma (0%, 0/42) or 27 cases of urothelial carcinoma with squamous differentiation (0%, 0/15). p16 expression was detected in 13 cases (31%, 13/42) of squamous cell carcinoma and 9 cases (33%, 9/27) of urothelial carcinoma with squamous differentiation. There was no correlation between p16 expression and the presence of HPV infection in squamous cell carcinoma of the bladder or urothelial carcinoma with squamous differentiation. Our data suggest that HPV does not play a role in the development of squamous cell carcinoma of the urinary bladder or urothelial carcinoma with squamous differentiation. p16 expression should not be used as a surrogate marker for evidence of HVP infection in either squamous cell carcinoma of the urinary bladder or urothelial carcinoma with squamous differentiation as neither HVP DNA nor protein is detectable in these neoplasms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684221     DOI: 10.1038/modpathol.2012.103

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot.

Authors:  Renate Pichler; Wegene Borena; Georg Schäfer; Claudia Manzl; Zoran Culig; Sebastian List; Sabrina Neururer; Dorothee Von Laer; Isabel Heidegger; Helmut Klocker; Wolfgang Horninger; Hannes Steiner; Andrea Brunner
Journal:  World J Urol       Date:  2015-03-19       Impact factor: 4.226

2.  Association of human herpes, papilloma and polyoma virus families with bladder cancer.

Authors:  Georgios I Panagiotakis; Danae Papadogianni; Maria N Chatziioannou; Ismini Lasithiotaki; Dimitrios Delakas; Demetrios A Spandidos
Journal:  Tumour Biol       Date:  2012-09-13

3.  Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder.

Authors:  Hind N Warzecha; Falko Fend; Julia Steinhilber; Harald Abele; Melanie Henes; Niklas Harland; Annette Staebler
Journal:  Virchows Arch       Date:  2017-06-07       Impact factor: 4.064

4.  Diagnostic Usefulness of p16 Immunohistochemistry for some Epithelial Lesions in the Pathology Service of Sultan Qaboos University Hospital.

Authors:  Iman Al-Ghafri; Samia Al-Husseini; Afrah Al-Rashdi; Mohammad Arafa
Journal:  Maedica (Bucur)       Date:  2021-12

5.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

Review 6.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

7.  The clinicopathological features of metastatic tumors of the bladder: analysis of 25 cases.

Authors:  Luhua Wang; Guoxin Song; Weiming Zhang; Zhihong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

8.  Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study.

Authors:  Sebastian C Schmid; Leonore Thümer; Tibor Schuster; Thomas Horn; Florian Kurtz; Julia Slotta-Huspenina; Judith Seebach; Michael Straub; Tobias Maurer; Michael Autenrieth; Hubert Kübler; Margitta Retz; Ulrike Protzer; Jürgen E Gschwend; Dieter Hoffmann
Journal:  Infect Agent Cancer       Date:  2015-09-21       Impact factor: 2.965

9.  HRAS mutations are frequent in inverted urothelial neoplasms.

Authors:  Andrew S McDaniel; Yali Zhai; Kathleen R Cho; Saravana M Dhanasekaran; Jeffrey S Montgomery; Ganesh Palapattu; Javed Siddiqui; Todd Morgan; Ajjai Alva; Alon Weizer; Cheryl T Lee; Arul M Chinnaiyan; Michael J Quist; Catherine S Grasso; Scott A Tomlins; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-06-18       Impact factor: 3.466

10.  Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection.

Authors:  Julie Steinestel; Marcus V Cronauer; Johannes Müller; Andreas Al Ghazal; Peter Skowronek; Annette Arndt; Klaus Kraft; Mark Schrader; Andres J Schrader; Konrad Steinestel
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.